Buy Rating Affirmed for BridgeBio Pharma on Acoramidis' Positive ATTR-CM Trial Outcomes
TipRanksApr 8 05:46 ET
Reported Sunday, BridgeBio Pharma Presented Results From The Exploratory Cardiac Magnetic Resonance Imaging Substudy Of ATTRibute-CM, Its Phase 3 Trial Of Acoramidis In ATTR-CM
- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression- T
BenzingaApr 8 02:50 ET
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent With Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented results from the exploratory CMR imaging substudy of ATTRibute-CM, its Phase 3 trial of acoramidis in ATTR-CM.
BridgeBio PharmaApr 7 00:00 ET
Buy Rating Justified for BridgeBio Pharma Amidst Promising Long-Term Market Prospects for ATTR-CM Treatments
TipRanksMar 24 21:47 ET
BridgeBio Pharma Price Target Raised to $45.00/Share From $35.00 by JP Morgan
BridgeBio Pharma Price Target Raised to $45.00/Share From $35.00 by JP Morgan
Dow JonesMar 20 06:38 ET
BridgeBio Pharma Is Maintained at Overweight by JP Morgan
BridgeBio Pharma Is Maintained at Overweight by JP Morgan
Dow JonesMar 20 06:38 ET
Express News | JP Morgan Maintains Overweight on BridgeBio Pharma, Raises Price Target to $45
Moomoo 24/7Mar 20 06:28 ET
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Jazz Pharmaceuticals (JAZZ)
TipRanksMar 20 06:10 ET
BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases a
BridgeBio PharmaMar 20 00:00 ET
Cantor Fitzgerald Adjusts Price Target on BridgeBio Pharma to $70 From $60, Maintains Overweight Rating
BridgeBio Pharma (BBIO) has an average outperform rating and a price target range of $33 to $70, according to analysts polled by Capital IQ. Price: 28.19, Change: +0.38, Percent Change: +1.37
MT NewswiresMar 19 09:55 ET
BridgeBio Pharma Price Target Raised to $70.00/Share From $60.00 by Cantor Fitzgerald
BridgeBio Pharma Price Target Raised to $70.00/Share From $60.00 by Cantor Fitzgerald
Dow JonesMar 19 08:45 ET
Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $70
Cantor Fitzgerald analyst Josh Schimmer maintains BridgeBio Pharma with a Overweight and raises the price target from $60 to $70.
Analyst UpgradesMar 19 08:35 ET
BridgeBio Pharma Is Maintained at Overweight by Cantor Fitzgerald
BridgeBio Pharma Is Maintained at Overweight by Cantor Fitzgerald
Dow JonesMar 11 09:26 ET
Express News | Cantor Fitzgerald Maintains Overweight on BridgeBio Pharma, Raises Price Target to $60
Moomoo 24/7Mar 11 09:16 ET
Analysts Have Conflicting Sentiments on These Healthcare Companies: PepGen Inc. (PEPG), BridgeBio Pharma (BBIO) and Amedisys (AMED)
TipRanksMar 6 23:20 ET
BridgeBio Prices $250M Stock Offering
Seeking AlphaMar 6 05:59 ET
BridgeBio: J.P. Morgan, Cantor and Mizuho Acting as Book-Running Managers >BBIO
BridgeBio: J.P. Morgan, Cantor and Mizuho Acting as Book-Running Managers >BBIO
Dow JonesMar 6 00:08 ET
BridgeBio Sees Gross Proceeds at $250.0M Excluding Exercise of Underwriters' Option>BBIO
BridgeBio Sees Gross Proceeds at $250.0M Excluding Exercise of Underwriters' Option>BBIO
Dow JonesMar 6 00:07 ET
BridgeBio Pharma Underwritten Offering of 8,620,690 Shares Priced at $29.00 Each >BBIO
BridgeBio Pharma Underwritten Offering of 8,620,690 Shares Priced at $29.00 Each >BBIO
Dow JonesMar 6 00:06 ET
BridgeBio Has Granted Underwriters Option for Additional 1,293,103 Shares >BBIO
BridgeBio Has Granted Underwriters Option for Additional 1,293,103 Shares >BBIO
Dow JonesMar 6 00:06 ET
No Data
No Data